Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX – Get Free Report) have received an average recommendation of “Buy” from the four brokerages that are presently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $71.25.
A number of research analysts recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Cidara Therapeutics in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $120.00 price target on shares of Cidara Therapeutics in a report on Monday, April 8th. Needham & Company LLC increased their price objective on shares of Cidara Therapeutics from $3.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday. Finally, WBB Securities reissued a “strong-buy” rating and set a $40.00 target price on shares of Cidara Therapeutics in a research note on Thursday.
View Our Latest Report on Cidara Therapeutics
Cidara Therapeutics Stock Up 5.8 %
Hedge Funds Weigh In On Cidara Therapeutics
Hedge funds have recently made changes to their positions in the business. Raymond James Financial Services Advisors Inc. lifted its stake in Cidara Therapeutics by 25.2% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 79,119 shares of the biotechnology company’s stock valued at $75,000 after purchasing an additional 15,912 shares during the last quarter. Flagship Harbor Advisors LLC bought a new position in shares of Cidara Therapeutics in the third quarter valued at $28,000. Finally, Pale Fire Capital SE acquired a new stake in shares of Cidara Therapeutics during the 3rd quarter valued at $51,000. Institutional investors and hedge funds own 35.82% of the company’s stock.
About Cidara Therapeutics
Cidara Therapeutics, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
Read More
- Five stocks we like better than Cidara Therapeutics
- What Does a Stock Split Mean?
- Hasbro’s Management Made All the Right Calls This Quarter
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.